$ALMS News

Last published 1mo ago

1mo agoALMSAlumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresGlobeNewswire– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching
2mo agoALMSAlumis to Participate in Upcoming September Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated
2mo agoALMSAlumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)GlobeNewswire– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support
3mo agoALMSAlumis Reports Second Quarter 2026 Financial Results and Highlights Recent AchievementsGlobeNewswire– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to submit its New Drug Application to FDA for
3mo agoALMSEnvudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral TherapiesGlobeNewswire– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – Favorable long-term safety and tolerability profile remained consistent with
6mo agoALMSAlumis Reports First Quarter 2026 Financial Results and Highlights Recent AchievementsGlobeNewswire– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements
7mo agoALMSAlumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque PsoriasisGlobeNewswireEnvudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality‑of‑life improvements and itch relief emerged ahead
8mo agoALMSAlumis to Present at the Leerink Partners Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today
9mo agoALMSAlumis to Participate in Upcoming February Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today
10mo agoALMSAlumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated
10mo agoALMSAlumis Announces Pricing of Upsized Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated
10mo agoALMSAlumis Announces Proposed Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated
10mo agoALMS BFRG CYCN KBLBMorning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into FocusGlobeNewswireDENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and
10mo agoALMSAlumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque PsoriasisGlobeNewswire– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing
12mo agoALMSAlumis Reports Third Quarter 2025 Financial Results and Highlights Recent ProgressGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated
1y agoALMSAlumis to Participate in Upcoming November Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today
1y agoALMSAlumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum TranscriptEarnings Call Transcripts
1y agoALMSAlumis to Participate in Upcoming September Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today
1y agoALMSAlumis Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire–Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b LUMUS clinical trial for
1y agoALMSAlumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus ErythematosusGlobeNewswire-Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients
1y agoALMSAlumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate SecretaryGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today
1y agoALMSAlumis to Present at the Jefferies Global Healthcare Investor ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today
1y agoALMSAlumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque PsoriasisGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today
1y agoALMSAlumis Completes Merger with ACELYRINGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today
1y agoALMSAlumis Reports First Quarter 2025 Financial Results and Highlights Recent AchievementsGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and
1y agoALMS SLRNAlumis Stockholders Approve Merger with ACELYRINGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and
1y agoALMS SLRNACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesGlobeNewswireLOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today
1y agoALMS SLRNLeading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with AlumisGlobeNewswireACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the
1y agoALMS SLRNACELYRIN Reiterates Benefits of Value-Maximizing Combination with AlumisGlobeNewswireSpecial Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc.
1y agoALMS SLRNAlumis and ACELYRIN Announce Amended Merger AgreementGlobeNewswireACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on
1y agoALMS SLRNAlumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed MergerGlobeNewswireStockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote "FOR" the merger Transaction expected to be completed in second
1y agoALMSAlumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in JapanGlobeNewswire- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales
1y agoALMSAlumis Reports Year End 2024 Financial Results and Highlights Recent AchievementsGlobeNewswire– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD
1y agoALMSAlumis to Present at Leerink's 2025 Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes
1y agoALMSLate-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in PsoriasisGlobeNewswireESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupusPhase 2 OLE data of ESK-001 at 40 mg BID
1y agoALMS SLRNACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerGlobeNewswireCombined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC.
1y agoALMS SLRNAlumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed MergerGlobeNewswireSOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS) ("Alumis") and ACELYRIN, INC. (NASDAQ:SLRN) ("ACELYRIN") today reaffirmed their commitment to merge in an
1y agoALMS SLRNACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis MergerGlobeNewswireAll-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on
1y agoALMSAlumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data ReadoutGlobeNewswire– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – – Additional Phase 2 e-poster presentations to
1y agoALMSAlumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative DiseasesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS) ("Alumis" or the "Company"), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to
1y agoALMS SLRNACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra BiosciencesGlobeNewswireLOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today
1y agoALMSAlumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes
1y agoALMS SLRNAlumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesGlobeNewswireTopline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on
1y agoALMSAlumis Strengthens Leadership Team with Key AppointmentsGlobeNewswireJack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies at global biopharmaceutical companies Sara Klein promoted to Chief Legal
1y agoALMSAlumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005GlobeNewswire– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable pharmacokinetic profile in CNS and periphery – – Data support advancement to Phase 2
1y agoALMSAlumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes
1y agoALMSAlumis Reports Third Quarter 2024 Financial Results and Highlights Recent AchievementsGlobeNewswire– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global
2y agoALMSAlumis to Participate in Guggenheim's Inaugural Healthcare Innovation ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes
2y agoALMSLate-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE StudyGlobeNewswire28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75Three additional data presentations further support ESK-001's potential to offer a
2y agoALMSAlumis to Participate in Upcoming September Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes